Effects of GSK v Teva ripple after SCOTUS denies cert

Last week (May 15), the Supreme Court denied certiorari in GlaxoSmithKline v Teva Pharms USA (GSK v Teva), locking in the US Court of Appeals for the Federal Circuit’s second panel decision which held that Teva’s attempted section viii carve-out of an indication covered by a patented method of use was not ‘skinny’ enough to avoid being liable for infringement.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

article

Teva loses plea against GSK’s $235m ‘skinny label’ win

16 May 2023 The US Supreme Court knocks back Teva’s challenge to GSK’s damages win | Decision issued despite US solicitor general warning that the earlier decision ‘threatens significant harm’ to the market.

Big Pharma

AstraZeneca prevails in GSK royalties row at UK High Court

6 April 2023 Feud involved a blockbuster cancer drug belonging to a family of PARP inhibitors | GSK unit failed to persuade the court of the merits of its ‘certain uses’ argument.

Big Pharma

GSK targets Pfizer over newly approved RSV vaccine

7 August 2023 GSK argues that its US rival knew of its patented technology seven years after research began | Blockbuster respiratory vaccines, world’s first of their kind, received US approval in May.

More on this story

article

Teva loses plea against GSK’s $235m ‘skinny label’ win

Big Pharma

AstraZeneca prevails in GSK royalties row at UK High Court

6 April 2023 Feud involved a blockbuster cancer drug belonging to a family of PARP inhibitors | GSK unit failed to persuade the court of the merits of its ‘certain uses’ argument.

Big Pharma

GSK targets Pfizer over newly approved RSV vaccine

More on this story

article

Teva loses plea against GSK’s $235m ‘skinny label’ win

Big Pharma

AstraZeneca prevails in GSK royalties row at UK High Court

6 April 2023 Feud involved a blockbuster cancer drug belonging to a family of PARP inhibitors | GSK unit failed to persuade the court of the merits of its ‘certain uses’ argument.

Big Pharma

GSK targets Pfizer over newly approved RSV vaccine